Beam Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
December 17, 2024 07:00 ET
|
Beam Therapeutics
CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting
December 08, 2024 13:45 ET
|
Beam Therapeutics
NHP Data Showed CD117 Monoclonal Antibody (mAb) Conditioning Successfully Achieved Long-term Engraftment of Base-edited Hematopoietic Stem Cells and Induced Robust Levels of Hemoglobin F mAb Dosing...
Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting
December 07, 2024 11:30 ET
|
Beam Therapeutics
All Seven Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to <40%, and Resolution of Anemia Post-BEAM-101 Treatment Initial Safety...
Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer
December 06, 2024 07:00 ET
|
Beam Therapeutics
CAMBRIDGE, Mass., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the...
Beam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial Leader
December 04, 2024 07:00 ET
|
Beam Therapeutics
CAMBRIDGE, Mass., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the...
Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference
November 12, 2024 16:01 ET
|
Beam Therapeutics
CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
Beam Therapeutics to Present Data Across Hematology Franchise, Including First Clinical Data for BEAM-101 in Sickle Cell Disease and ESCAPE Non-human Primate Data, at American Society of Hematology (ASH) Annual Meeting
November 05, 2024 09:00 ET
|
Beam Therapeutics
Initial Results from BEACON Phase 1/2 Clinical Trial Demonstrate Potential for Differentiation of Base Editing and BEAM-101 Preclinical ESCAPE Data Establish Proof-of-concept for...
Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority Programs
November 05, 2024 06:30 ET
|
Beam Therapeutics
Initial Clinical Data for BEAM-101 and Preclinical Non-human Primate Data for ESCAPE Accepted for Presentation at American Society of Hematology (ASH) Annual Meeting 35 Patients Enrolled and Eight...
Beam Therapeutics to Hold Conference Call to Discuss Third Quarter 2024 Financial Results and Abstracts Accepted for Presentation at ASH Annual Meeting
October 29, 2024 06:30 ET
|
Beam Therapeutics
CAMBRIDGE, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the...
Beam Therapeutics Reports Pipeline Updates and Second Quarter 2024 Financial Results
August 06, 2024 06:30 ET
|
Beam Therapeutics
U.S. Food and Drug Administration Cleared Investigational New Drug (IND) Application for BEAM-301 in Glycogen Storage Disease Type Ia (GSDIa) More than 20 Patients Enrolled and Six Patients Dosed...